---
title: "Ozempic (semaglutide) in type 2 diabetes: Safety questions"
description: "Safety questions on Ozempic (semaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Ozempic cause thyroid cancer (boxed warning)? Who should not take Ozempic (contraindications)? What are the most common side effects of Ozempic injection? What are the most common side effects of the Ozempic pill? 13 further questions follow. 17 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ozempic (semaglutide) in type 2 diabetes: Safety questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Ozempic](https://www.novo-pi.com/ozempic.pdf), [Ozempic tablets](https://www.novo-pi.com/ozempictablets.pdf)

## Safety

<a id="ozempic-boxed-warning"></a>

### Does Ozempic cause thyroid cancer (boxed warning)?

> “WARNING: RISK OF THYROID C-CELL TUMORS
>
> In rodents, semaglutide causes dose-dependent and treatment-duration- dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic<sup>®</sup> causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
> Ozempic<sup>®</sup> is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic<sup>®</sup> and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic<sup>®</sup>”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=WARNING%3A%20RISK%20OF%20THYROID%20C%2DCELL,MTC%20in%20patients%20treated%20with)

> “Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Risk%20of%20Thyroid%20C%2DCell%20Tumors%3A,physical%20examination%20or%20neck%20imaging)

<a id="ozempic-contraindications"></a>

### Who should not take Ozempic (contraindications)?

> “Ozempic<sup>®</sup> is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic<sup>®</sup>. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic<sup>®</sup>”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Serious%20hypersensitivity%20reactions%20including%20anaphylaxis%20and%20angioedema%20have%20been%20reported%20with)

<a id="ozempic-pen-side-effects"></a>

### What are the most common side effects of Ozempic injection?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “The most common adverse reactions reported in ≥5% of patients taking Ozempic<sup>®</sup> injection and Ozempic<sup>®</sup> tablets are nausea, vomiting, diarrhea, abdominal pain, and constipation. Decreased appetite was also reported in ≥5% of patients taking semaglutide tablets
> The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation
> Ozempic<sup>®</sup> injection: In placebo-controlled trials, discontinuation due to GI adverse reactions was 3.1% and 3.8% for the Ozempic<sup>®</sup> injection 0.5 mg and 1 mg dose, respectively, compared with 0.4% for placebo”

Source: [OZEMPIC: Safety & Side Effects, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/safety-profile.html#:~:text=The%20most%20common%20adverse%20reactions,compared%20with%200.4%25%20for%20placebo)

> “Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of 
> OZEMPIC<sup>®</sup>-Treated Patients with Type 2 Diabetes Mellitus
> Adverse Reaction
> Placebo 
> (N=262)
> %
> OZEMPIC<sup>®</sup> 0.5 mg 
> (N=260)
> %
> OZEMPIC<sup>®</sup> 1 mg 
> (N=261)
> %
> Nausea
> 6.1
> 15.8 
> 20.3 
> Vomiting
> 2.3 
> 5
> 9.2 
> Diarrhea
> 1.9 
> 8.5 
> 8.8 
> Abdominal pain
> 4.6
> 7.3
> 5.7
> Constipation
> 1.5 
> 5
> 3.1”

Source: [OZEMPIC: Ozempic®, page 3, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=3)

> “In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more 
> frequently among patients receiving OZEMPIC<sup>®</sup> than placebo (placebo 15.3%, OZEMPIC<sup>®</sup> 
> 0.5 mg 32.7%, OZEMPIC<sup>®</sup> 1 mg 36.4%). The majority of reports of nausea, vomiting, and/or 
> diarrhea occurred during dose escalation. More patients receiving OZEMPIC<sup>®</sup> 0.5 mg (3.1%) and 
> OZEMPIC<sup>®</sup> 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than 
> patients receiving placebo (0.4%).”

Source: [OZEMPIC: Ozempic®, page 3, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=3)

Note: Table 1 rows list placebo, OZEMPIC® 0.5 mg, and OZEMPIC® 1 mg percentages, in that order.

<a id="ozempic-pill-side-effects"></a>

### What are the most common side effects of the Ozempic pill?

Applies to: Type 2 diabetes in adults; Ozempic tablets (pill)

> “Semaglutide tablets: 4% and 8% of patients discontinued semaglutide tablets 7 mg and 14 mg, respectively, due to GI adverse reactions, compared with 1% of patients receiving placebo”

Source: [OZEMPIC: Safety & Side Effects, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/safety-profile.html#:~:text=Semaglutide%20tablets%3A%204%25%20and%208%25,1%25%20of%20patients%20receiving%20placebo)

> “Table 2. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of 
> Semaglutide Tablets-Treated Patients with Type 2 Diabetes Mellitus
> Adverse Reaction
> Placebo
> (N=362)
> %
> Semaglutide 
> Tablets 7 mg
> (N=356)
> %
> Semaglutide 
> Tablets 14 mg
> (N=356)
> %
> Nausea
> 6
> 11
> 20
> Abdominal Pain
> 4
> 10
> 11
> Diarrhea 
> 4
> 9
> 10
> Decreased appetite 
> 1
> 6
> 9
> Vomiting
> 3
> 6
> 8
> Constipation
> 2
> 6
> 5”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=4)

> “In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently 
> among patients who received semaglutide tablets than placebo: semaglutide tablets 14 mg once daily 
> (41%), semaglutide tablets 7 mg once daily (32%) and placebo (21%), including severe reactions 
> (semaglutide tablets 14 mg 2.0%, semaglutide tablets 7 mg 0.6%, placebo 0.3%). The majority of 
> reports of nausea, vomiting and/or diarrhea occurred during dose escalation. A greater percentage 
> of patients who received semaglutide tablets 14 mg once daily (8%) and semaglutide tablets 7 mg 
> once daily (4%) discontinued treatment due to gastrointestinal adverse reactions than patients who 
> received placebo (1%).”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=4)

> “The data provided on the Rybelsus<sup>®</sup> PIONEER Clinical Trial program are based on clinical trials involving Rybelsus<sup>®</sup> (3 mg, 7 mg, and 14 mg). The efficacy and safety of Ozempic<sup>®</sup> pill (1.5 mg, 4 mg, and 9 mg) have been established based on adequate and well-controlled studies of Rybelsus<sup>®</sup> (3 mg, 7 mg, and 14 mg).<sup>2</sup>”

Source: [OZEMPIC: Safety & Side Effects, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/safety-profile.html#:~:text=The%20data%20provided%20on%20the,%283%20mg%2C%207%20mg%2C%20and%2014)

This passage is in a collapsed section of the page; select: Adverse events ≥5% in placebo-controlled trials with semaglutide tablets

Note: Table 2 rows list placebo, semaglutide tablets 7 mg, and semaglutide tablets 14 mg percentages, in that order.

<a id="ozempic-2mg-side-effects"></a>

### Does Ozempic 2 mg cause more side effects than Ozempic 1 mg?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “In a 40-week, randomized, active-controlled trial with 959 patients treated with Ozempic<sup>®</sup> injection 1 mg or Ozempic<sup>®</sup> injection 2 mg once weekly as add-on to metformin with or without sulfonylurea treatment for 40 weeks, no new safety signals were identified<sup>1</sup> 
> In the trial with Ozempic<sup>®</sup> injection 1 mg and 2 mg, GI adverse reactions occurred more frequently among patients receiving Ozempic<sup>®</sup> injection 2 mg (34.0%) vs Ozempic<sup>®</sup> injection 1 mg (30.8%)<sup>1</sup>”

Source: [OZEMPIC: Safety & Side Effects, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/safety-profile.html#:~:text=In%20a%2040%2Dweek%2C%20randomized%2C%20active%2Dcontrolled,injection%201%20mg)

Note: The safety page gives 959 patients for this trial; its study design section and the A1C results page give 961 randomized patients.

<a id="ozempic-flow-safety"></a>

### What side effects were reported with Ozempic in the FLOW trial?

Applies to: Adults with type 2 diabetes and chronic kidney disease; Ozempic injection

> “In FLOW, the most common adverse event of special interest was diabetic retinopathy<sup>9</sup>
> The incidence of serious adverse events related to a cardiovascular disorder was approximately 15% with Ozempic<sup>®</sup> injection and 18% with placebo<sup>9</sup>
> In the FLOW trial, safety data collection was limited to serious adverse events and selected predefined categories of adverse events regardless of seriousness. There were no new serious or severe adverse reactions identified in this trial<sup>1</sup>”

Source: [OZEMPIC: Safety & Side Effects, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/safety-profile.html#:~:text=In%20FLOW%2C%20the%20most%20common,adverse%20reactions%20identified%20in%20this)

This passage is in a collapsed section of the page; select: Adverse events ≥5% in FLOW with Ozempic® injection

<a id="ozempic-soul-safety"></a>

### Ozempic pill long-term safety: what did the 4-year SOUL trial find?

Applies to: Adults with type 2 diabetes at high risk for major cardiovascular events; semaglutide tablets

> “Ozempic<sup>®</sup> tablets 1.5 mg, 4 mg, 9 mg are an updated formulation with increased bioavailability. This updated formulation is established with comparable mean exposure and peak concentration. The safety and effectiveness of Ozempic<sup>®</sup> tablets were established through adequate and well-controlled studies of semaglutide tablets 3 mg, 7 mg, 14 mg.<sup>7,9</sup>”

Source: [OZEMPIC: Cardiovascular Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/cv-outcomes/pill.html#:~:text=tablets%201.5%20mg%2C%204%20mg%2C,3%20mg%2C%207%20mg%2C%2014)

> “In a 4-year CV outcomes trial (Trial 7), 4,825 patients were randomized to semaglutide tablets for a 
> median follow-up of 49.6 months and 4,825 patients were randomized to placebo for a median follow-up 
> of 49.4 months [see Clinical Studies (14.4)]. Safety data collection was limited to serious adverse 
> events (including death), adverse events leading to discontinuation, and adverse events of special 
> interest. Study drug was permanently discontinued due to an adverse event in 15.5% of semaglutide 
> tablets-treated patients and 11.6% of placebo-treated patients.”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=4)

> “In a 4-year CV outcomes trial (Trial 7), cholelithiasis was reported in 1.1% of patients treated with semaglutide tablets 14 mg and in 0.9% of placebo-treated patients. In Trial 7, cholecystitis was reported in 1.1% treated with semaglutide tablets 14 mg and in 0.7% of placebo-treated patients.”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=In%20a%204%2Dyear%20CV%20outcomes,in%200.7%25%20of%20placebo%2Dtreated%20patients.)

Note: Trial 7 of the Prescribing Information has the same design and enrollment (9,650 patients) as SOUL.

<a id="ozempic-hypoglycemia"></a>

### Does Ozempic cause low blood sugar (hypoglycemia)?

> “Incidence of severe hypoglycemia was <1.5% across placebo-controlled trials with Ozempic<sup>®</sup> injection, (<1% for Ozempic<sup>®</sup> 1 mg and Ozempic<sup>®</sup> 2 mg in SUSTAIN FORTE), and <1% in placebo-controlled trials with semaglutide tablets<sup>1,2,a-c</sup>
> Patients receiving Ozempic<sup>®</sup> injection and semaglutide tablets, used in combination with insulin secretagogues (eg, sulfonylureas) or insulin, may have an increased risk of hypoglycemia, including severe hypoglycemia<sup>1,2</sup>
> When initiating Ozempic<sup>®</sup> injection and semaglutide tablets, patients may require a lower dose of the insulin secretagogue (such as sulfonylurea) or insulin to reduce the risk of hypoglycemia<sup>1-3</sup>”

Source: [OZEMPIC: Safety & Side Effects, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/safety-profile.html#:~:text=Incidence%20of%20severe%20hypoglycemia%20was,to%20reduce%20the%20risk%20of)

> “Add-on to Basal Insulin with or 
> without Metformin
> (30 weeks)
> N=132
> N=132
> N=131
> Severe<sup>†</sup> 
> 0%
> 0%
> 1.5%
> Documented symptomatic (≤70 mg/dL 
> glucose threshold)
> 15.2%
> 16.7%
> 29.8%
> Severe<sup>†</sup> or Blood Glucose Confirmed 
> Symptomatic (≤56 mg/dL glucose 
> threshold) 
> 5.3%
> 8.3%
> 10.7%”

Source: [OZEMPIC: Ozempic®, page 3, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=3)

> “<sup>†</sup> “Severe” hypoglycemia adverse reactions are episodes requiring the assistance of another person.”

Source: [OZEMPIC: Ozempic®, page 3, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=3)

> “Hypoglycemia was more frequent when OZEMPIC<sup>®</sup> was used in combination with a sulfonylurea 
> [see Warnings and Precautions (5.5), Clinical Studies (14)]. Severe hypoglycemia occurred in 
> 0.8% and 1.2% of patients when OZEMPIC<sup>®</sup> 0.5 mg and 1 mg, respectively, was coadministered 
> with a sulfonylurea. 
> Documented symptomatic hypoglycemia occurred in 17.3% and 24.4% of patients when 
> OZEMPIC<sup>®</sup> 0.5 mg and 1 mg, respectively, was coadministered with a sulfonylurea. Severe or 
> blood glucose confirmed symptomatic hypoglycemia occurred in 6.5% and 10.4% of patients 
> when OZEMPIC<sup>®</sup> 0.5 mg and 1 mg, respectively, was coadministered with a sulfonylurea.”

Source: [OZEMPIC: Ozempic®, page 3, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=3)

Note: Table 2 columns are placebo, OZEMPIC® 0.5 mg, and OZEMPIC® 1 mg, in that order. The safety page states <1.5% for severe hypoglycemia with Ozempic® injection; Table 2 of the Prescribing Information reports 1.5% with OZEMPIC® 1 mg added to basal insulin.

<a id="ozempic-pancreatitis"></a>

### Can Ozempic cause pancreatitis?

> “Acute Pancreatitis: Acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), with or without nausea or vomiting. If pancreatitis is suspected, discontinue Ozempic<sup>®</sup> and initiate appropriate management”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Acute%20Pancreatitis%3A%20Acute%20pancreatitis%2C%20including,and%20initiate%20appropriate%20management)

> “In glycemic control trials, acute pancreatitis was confirmed by adjudication in 7 OZEMPIC-
> treated patients (0.3 cases per 100 patient years) versus 3 in comparator-treated patients (0.2 
> cases per 100 patient years).”

Source: [OZEMPIC: Ozempic®, page 3, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=3)

> “Pancreatitis: In the pool of placebo- and active-controlled trials with semaglutide tablets, pancreatitis 
> was reported as a serious adverse event in 6 semaglutide tablets -treated patients (0.1 events per 100 
> patient years) versus 1 in comparator-treated patients (<0.1 events per 100 patient years).”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=4)

<a id="ozempic-retinopathy"></a>

### Can Ozempic worsen diabetic retinopathy?

> “Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic<sup>®</sup> injection (3%) compared to placebo (1.8%). In a pooled analysis of glycemic control trials, patients reported diabetic retinopathy related adverse reactions during the trial (4.2% with semaglutide tablets and 3.8% with comparator). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history.
> Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Diabetic%20Retinopathy%20Complications%3A%20In%20a,for%20progression%20of%20diabetic%20retinopathy)

> “The absolute risk increase for diabetic retinopathy complications 
> was larger among patients with a history of diabetic retinopathy at baseline (OZEMPIC<sup>®</sup> 8.2%, 
> placebo 5.2%) than among patients without a known history of diabetic retinopathy (OZEMPIC<sup>®</sup> 
> 0.7%, placebo 0.4%).”

Source: [OZEMPIC: Ozempic®, page 2, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=2)

<a id="ozempic-kidney-injury"></a>

### Can Ozempic cause acute kidney injury?

> “Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Ozempic<sup>®</sup> that could lead to volume depletion, especially during dosage initiation and escalation”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Acute%20Kidney%20Injury%20Due%20to,during%20dosage%20initiation%20and%20escalation)

<a id="ozempic-severe-gi-side-effects"></a>

### Can Ozempic cause severe stomach side effects?

> “Severe Gastrointestinal (GI) Adverse Reactions: Use of Ozempic<sup>®</sup> has been associated with GI adverse reactions, sometimes severe. In clinical trials, severe GI adverse reactions were reported more frequently among patients who received Ozempic<sup>®</sup> injection (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%); and severe GI adverse reactions were reported more frequently among patients who received semaglutide tablets (7 mg 0.6%, 14 mg 2%) than placebo (0.3%). Severe GI adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Severe%20Gastrointestinal%20%28GI%29%20Adverse%20Reactions%3A,postmarketing%20with%20GLP%2D1%20receptor%20agonists.)

<a id="ozempic-gastroparesis"></a>

### Can people with severe gastroparesis take Ozempic?

> “Ozempic<sup>®</sup> is not recommended in patients with severe gastroparesis”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=is%20not%20recommended%20in%20patients%20with%20severe%20gastroparesis)

> “OZEMPIC<sup>®</sup> is not recommended in patients with severe gastroparesis.”

Source: [OZEMPIC: Ozempic®, page 2, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=2)

> “RYBELSUS<sup>®</sup> and OZEMPIC<sup>®</sup> tablets are not recommended in patients with severe gastroparesis.”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=4)

Note: The second passage is from the Ozempic® injection Prescribing Information; the third is from the Prescribing Information for semaglutide tablets.

<a id="ozempic-gallbladder"></a>

### Can Ozempic cause gallbladder problems such as gallstones?

> “Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic<sup>®</sup> injection 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. In placebo-controlled trials to improve glycemic control, cholelithiasis was reported in 1% of patients treated with semaglutide tablets 7 mg. In a 4-year CV outcomes trial (Trial 7), cholelithiasis was reported in 1.1% of patients treated with semaglutide tablets 14 mg and in 0.9% of placebo-treated patients. In Trial 7, cholecystitis was reported in 1.1% treated with semaglutide tablets 14 mg and in 0.7% of placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Acute%20Gallbladder%20Disease%3A%20Acute%20events,appropriate%20clinical%20follow%2Dup%20are%20indicated)

<a id="ozempic-surgery-anesthesia"></a>

### What should patients taking Ozempic know before surgery or anesthesia?

> “Pulmonary Aspiration During General Anesthesia or Deep Sedation: Ozempic<sup>®</sup> delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic<sup>®</sup>”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Pulmonary%20Aspiration%20During%20General%20Anesthesia,procedures%20if%20they%20are%20taking)

> “Available data are insufficient to inform recommendations to mitigate the risk of pulmonary 
> aspiration during general anesthesia or deep sedation in patients taking OZEMPIC<sup>®</sup>, including 
> whether modifying preoperative fasting recommendations or temporarily discontinuing 
> OZEMPIC<sup>®</sup> could reduce the incidence of retained gastric contents. Instruct patients to inform 
> healthcare providers prior to any planned surgeries or procedures if they are taking OZEMPIC<sup>®</sup>.”

Source: [OZEMPIC: Ozempic®, page 3, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=3)

<a id="ozempic-hypersensitivity"></a>

### Can Ozempic cause allergic reactions?

> “Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic<sup>®</sup>. If hypersensitivity reactions occur, discontinue use of Ozempic<sup>®</sup>; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=Hypersensitivity%3A%20Serious%20hypersensitivity%20reactions%20%28e.g.%2C,with%20another%20GLP%2D1%20receptor%20agonist)

<a id="ozempic-overdose"></a>

### What should be done after an Ozempic overdose?

> “In the event of overdose, appropriate supportive treatment should be initiated according to the 
> patient’s clinical signs and symptoms. Consider contacting the Poison Help line (1-800-222-
> 1222) or a medical toxicologist for additional overdosage management recommendations. A 
> prolonged period of observation and treatment for these symptoms may be necessary, taking into 
> account the long half-life of OZEMPIC<sup>®</sup> of approximately 1 week.”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=4)

> “In the event of overdose, appropriate supportive treatment should be initiated according to the 
> patient’s clinical signs and symptoms. Consider contacting the Poison Help line (1-800-222-1222) 
> or a medical toxicologist for additional overdosage management recommendations. A prolonged 
> period of observation and treatment for these symptoms may be necessary, taking into account the 
> long half-life of semaglutide of approximately 1 week.”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=6)

Note: The first passage is from the Ozempic® injection Prescribing Information; the second is from the Prescribing Information for semaglutide tablets.

## Related pages
- [Medical information: Ozempic (semaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/access-and-coverage)
